Trial report in Tomography (Ann Arbor, Mich.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 5 institutions in 2 countries.
Mark MuziSchool of Medicine, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0002-8767-191X
Finbarr O'SullivanSchool of Mathematical Sciences, University College, T12 XF62 Cork, Ireland.
Timothy G PerkAIQ Solutions, Madison, WI 53717, USA.
John P MuziSchool of Medicine, University of Washington, Seattle, WA 98195, USA.
David A MankoffPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Robert JerajDepartment of Medical Physics, University of Wisconsin, Madison, WI 53705, USA.
Fenghai DuanDepartment of Biostatistics, Brown University, Providence, RI 02912, USA.
Evan Y YuSchool of Medicine, University of Washington, Seattle, WA 98195, USA.
University of Washington · USUniversity of Wisconsin–Madison · USBrown University · USUniversity College Cork · IEUniversity of Pennsylvania · US
Funding
ARRA - ADOPT New Technologies for RDC/CDMSU01CA080098 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI SCHNALL, MITCHELL D. · 1999 to 2011
$182.7M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
Hutchinson Center as Lead Academic Participating Site (UG1)UG1CA233328 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Yu · 2019 to 2026
$4.3M
ECOG-ACRIN-Based QIN Resource for Advancing Quantitative Cancer Imaging in Clinical TrialsU01CA190254 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI SCHNALL, MITCHELL D. · 2015 to 2019
$3.2M
Core Laboratory for Advanced PET and MRI image analysisR50CA211270 · NCI · UNIVERSITY OF WASHINGTON · PI Mark Muzi · 2017 to 2026
ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [
Indexed as
Prostatic Neoplasms, Castration-ResistantDasatinibFluoridesFluorine RadioisotopesHumansMalePositron-Emission TomographyPositron Emission Tomography Computed TomographySodium FluorideTomography, X-Ray ComputedDasatinibFluoridesFluorine RadioisotopesSodium Fluoride[18F]-FluorideACRIN 6687bone metastasesdasatinibmetastatic castration-resistant prostate cancer (mCRPC)PETprogression-free survival (PFS)Quantitative Total Bone Imaging (QTBI)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.